Search

Your search keyword '"BELARDI, JORGE"' showing total 567 results
Start Over Author "BELARDI, JORGE"
567 results on '"BELARDI, JORGE"'

202. Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents

Author

Tanabe, Kengo, primary, Serruys, Patrick W., additional, Degertekin, Muzaffer, additional, Guagliumi, Giulio, additional, Grube, Eberhard, additional, Chan, Charles, additional, Munzel, Thomas, additional, Belardi, Jorge, additional, Ruzyllo, Witold, additional, Bilodeau, Luc, additional, Kelbaek, Henning, additional, Ormiston, John, additional, Dawkins, Keith, additional, Roy, Louis, additional, Strauss, Bradley H., additional, Disco, Clemens, additional, Koglin, Jörg, additional, Russell, Mary E., additional, and Colombo, Antonio, additional

Published
2004
Full Text
View/download PDF

205. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial

Author

Kiemeneij, Ferdinand, primary, Serruys, Patrick W, additional, Macaya, Carlos, additional, Rutsch, Wolfgang, additional, Heyndrickx, Guy, additional, Albertsson, Per, additional, Fajadet, Jean, additional, Legrand, Victor, additional, Materne, Pierre, additional, Belardi, Jorge, additional, Sigwart, Ulrich, additional, Colombo, Antonio, additional, Goy, Jean-Jacques, additional, Disco, Clemens M.C, additional, and Morel, Marie-Angèle, additional

Published
2001
Full Text
View/download PDF

206. Safety of Intracoronary Administration of c-myc Antisense Oligomers After Percutaneous Transluminal Coronary Angioplasty (PTCA)

Author

Roqué, Fernando, primary, Mon, Guillermo, additional, Belardi, Jorge, additional, Rodriguez, Alfredo, additional, Grinfeld, Liliana, additional, Long, Robert, additional, Grossman, Steven, additional, Malcolm, Alasdair, additional, Zon, Gerald, additional, Ormont, Michael L., additional, Fischman, David L., additional, Shi, Yi, additional, and Zalewski, Andrew, additional

Published
2001
Full Text
View/download PDF

207. Randomized Comparison of Primary Stenting and Provisional Balloon Angioplasty Guided by Flow Velocity Measurement

Author

Serruys, Patrick W., primary, de Bruyne, Bernard, additional, Carlier, Stéphane, additional, Sousa, José Eduardo, additional, Piek, Jan, additional, Muramatsu, Toshiya, additional, Vrints, Chris, additional, Probst, Peter, additional, Seabra-Gomes, Ricardo, additional, Simpson, Ian, additional, Voudris, Vasilis, additional, Gurné, Olivier, additional, Pijls, Nico, additional, Belardi, Jorge, additional, van Es, Gerrit-Anne, additional, Boersma, Eric, additional, Morel, Marie-Angèle, additional, and van Hout, Ben, additional

Published
2000
Full Text
View/download PDF

209. Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries

Author

Serruys, Patrick W., primary, Emanuelsson, Håkan, additional, van der Giessen, Wim, additional, Lunn, Anthony C., additional, Kiemeney, Ferdinand, additional, Macaya, Carlos, additional, Rutsch, Wolfgang, additional, Heyndrickx, Guy, additional, Suryapranata, Harry, additional, Legrand, Victor, additional, Goy, Jean Jacques, additional, Materne, Pierre, additional, Bonnier, Hans, additional, Morice, Marie-Claude, additional, Fajadet, Jean, additional, Belardi, Jorge, additional, Colombo, Antonio, additional, Garcia, Eulogio, additional, Ruygrok, Peter, additional, de Jaegere, Peter, additional, and Morel, Marie-Angèle, additional

Published
1996
Full Text
View/download PDF

210. 741-1 Clinical Experience with Heparin-Coated Stents–The Benestent II Pilot Phase 1

Author

Emanuelsson, Håkan, primary, Serruys, Patrick W., additional, Belardi, Jorge, additional, Bonnier, Hans, additional, Colombo, Antonio, additional, Fajadet, Jean, additional, Goy, Jean-Jacques, additional, Heyndrickx, Guy, additional, de Jaegere, Peter, additional, Legrand, Victor, additional, Macaya, Cadas, additional, Materne, Pierre, additional, Rutsch, Wolfgang, additional, Sigwart, Ulrich, additional, and Suryapranata, Harry, additional

Published
1995
Full Text
View/download PDF

213. Direct Stenting with TAXUS Stents Seems to be as Safe and Effective as with Predilatation.

Author

Silber, Sigmund, Hamburger, Jaap, Grube, Eberhard, Pfisterer, Matthias, Belardi, Jorge, Webb, John, Zmudka, Krzysztof, Nienaber, Christoph, Hauptman, Karl, Rutsch, Wolfgang, Dawkins, Keith, Drzewiecki, Janusz, Koglin, Jörg, and Colombo, Antonio

Abstract

Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2004
Full Text
View/download PDF

214. General Utilities of Multislice Tomography in the Cardiac Field.

Author

Carrascosa, Patricia Marina, Capuñay, Carlos María, Parodi, Juan Carlos, Padilla, Lucio Tiburcio, Johnson, Peter, Carrascosa, Jorge Manuel, Chandra, Shalabh, Smith, Dava, and Belardi, Jorge

Abstract

Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2003
Full Text
View/download PDF

215. Surgical Risk Scoring in TAVR: Still Needed? A Metaregression Analysis.

Author

Baro, Rocio, Cura, Fernando, Belardi, Jorge, Brugaletta, Salvatore, and Lamelas, Pablo

Abstract

Several randomized controlled trials evaluating the effectiveness of transcatheter aortic valve replacement (TAVR) against surgical aortic valve replacement have been published to date. The fact that higher risk populations were implemented first does not necessarily mean that they benefit more from a TAVR procedure. We performed meta-analysis of the 8 randomized clinical trials performing TAVR for both mortality and stroke outcomes. Meta-regression was used to evaluate the association between mean surgical risk using the Society of Thoracic Surgeons (STS) score and hazard ratio observed in each of the trials. Overall, TAVR was associated with a significant reduction of both mortality and stroke across the whole spectrum of patients enrolled, with no evidence of significant heterogeneity. Metaregression analysis does not suggest a statistically significant association between STS score and hazard ratio for both mortality and stroke. This observation suggests reconsidering the use of risk scores to prioritize TAVR utilization in higher risk patients, while more focus should be done on patient's life expectancy related to TAVR durability. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

216. StentBoost Visualization for the Evaluation of Coronary Stent Expansion During Percutaneous Coronary Interventions

Author

Cura, Fernando, Albertal, Mariano, Candiello, Alfonsina, Nau, Gerardo, Bonvini, Victor, Tricherri, Hernan, Padilla, Lucio, and Belardi, Jorge

Abstract

Inadequate stent implantation is associated with stent thrombosis and restenosis. StentBoost can enhance stent visualization and evaluate stent expansion. Currently, there are limited comparison studies between StentBoost and intravascular ultrasound (IVUS). We aimed to test the correlation and agreement between IVUS and StentBoost measurements. From December 2010 to December 2011, 38 patients (54 stents) were analyzed using IVUS and StentBoost. Minimal stent diameter and proximal and distal edge stent diameter were compared between imaging techniques using Pearson correlation and Bland–Altman scatter plot. There was good correlation between StentBoost and IVUS measurements regarding minimal stent diameter (p< 0.001 in all stent portions) and an optimal agreement between IVUS and StentBoost, while lesser agreement was found between IVUS and quantitative coronary angiography. The assessment of stent implantation using StentBoost showed an adequate correlation and agreement with IVUS. This easily applicable angiographic technique can be used to guide stent implantation.

Published
2013
Full Text
View/download PDF

218. Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis 2-Year Results From a Pooled Analysis

Author

Richardt, Gert, Leschke, Matthias, Abdel-Wahab, Mohamed, Toelg, Ralph, El-Mawardy, Mohamed, Serruys, Patrick W., Silber, Sigmund, Windecker, Stephan, Belardi, Jorge A., Neumann, Franz-Josef, and Widimsky, Petr

Subjects
zotarolimus-eluting stent, clinical outcome, PCI, in-stent restenosis
Abstract

ObjectivesThis study sought to assess the clinical safety and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in patients with in-stent restenosis (ISR) from 2 large trials.BackgroundISR treatment is associated with higher rates of subsequent cardiac events compared with treatment of de novo lesions. Although drug-eluting stents (DES) are an option, second-generation DES are largely untested in the treatment of ISR.MethodsA total of 3,489 patients were pooled from the RAC (RESOLUTE All Comers) trial and the RESOLUTE International (RINT) registry. Two-year clinical endpoints included clinically driven target lesion revascularization (TLR), target lesion failure (TLF), cardiac death (CD), target vessel myocardial infarction (TVMI), combined CD or TVMI (CD/TVMI), and Academic Research Consortium definite and probable stent thrombosis (ST).ResultsOverall, 281 patients (8.1%) received an R-ZES for ISR. Two-year TLR and TLF rates were significantly higher in ISR patients than in non-ISR patients (TLR: 12.7% vs. 4.3%, p = 0.003; TLF: 17.4% vs. 9.4%, p = 0.007); however, the CD/TVMI rate was not (6.9% vs. 6.1%, p = 0.711). Seven ISR patients had ST. Two-year outcomes by ISR stent type were similar: bare-metal stent (BMS)-ISR TLR was 12.5% and TLF was 17.2%; DES-ISR TLR was 13.0% and TLF was 18.8%. CD/TVMI was 7.3% and 7.2% for BMS-ISR and DES-ISR, respectively.ConclusionsUsing R-ZES to treat ISR appears equally safe in BMS-ISR and DES-ISR, with CD/TVMI rates comparable to 2-year outcomes in other clinical trials. Although revascularization rates are still higher in ISR lesions, the R-ZES offers an effective alternative for treatment of BMS-ISR and DES-ISR.(Randomized, Two-Arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent [RESOLUTE-AC]; NCT00617084; and RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a ‘Real-World’ Patient Population [RINT]; NCT00752128)

Full Text
View/download PDF

219. Real-World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final 3-Year Report of the RESOLUTE International Study

Author

BELARDI, JORGE A, WIDIMSKÝ, PETR, NEUMANN, FRANZ-JOSEF, MAURI, LAURA, and ALBERTAL, MARIANO

Abstract

Objectives: We evaluated the safety and effectiveness of the Resolute™ zotarolimus-eluting stent (R-ZES) in real-world clinical practice through 3 years. Background: A randomized comparison of the R-ZES and the XIENCE V™ everolimus-eluting stent showed no difference in any outcomes through 3-year follow-up in high-volume academic centers. RESOLUTE International is a confirmatory trial designed to evaluate the R-ZES in real-world clinical practice. Methods: RESOLUTE International is a single arm, observational trial that enrolled 2,349 patients from 88 centers with only a few inclusion and exclusion criteria. The primary end-point was the composite of cardiac death and target vessel myocardial infarction (TV-MI) at 1 year. Secondary end-points include target lesion failure (TLF), target vessel revascularization (TVR), and their components, and stent thrombosis (ST). Results: At 3 years 97.2% of patients completed clinical follow-up. The mean age was 63.4 ± 11.2 years, 77.8% were male, and 30.4% had diabetes. The average number of stents per patient was 1.6 ± 1.0; and mean stent length was 30.9 ± 20.5 mm. Dual antiplatelet therapy was used in 91.1% of patients at 1 year, 43.0% at 2 years, and 34.6% at 3 years. Cardiac death and TV-MI occurred in 161 patients (7.0%). There were 6 (0.3%) very late ST events for a total ST rate of 1.1% through 3 years. The rates of clinically driven target lesion revascularization (TLR), TVR, and TLF were 5.7%, 7.4%, and 11.4%, respectively. Conclusions: The safety and effectiveness of the R-ZES through 3 years in this real-world all-comer study was consistent with previously reported all-comer trials. (J Interven Cardiol 2013;26:515-523)

Published
2013
Full Text
View/download PDF

225. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation

Author

Silber, Sigmund, Kirtane, Ajay J., Belardi, Jorge A., Liu, Minglei, Brar, Sandeep, Rothman, Martin, Windecker, Stephan, Silber, Sigmund, Kirtane, Ajay J., Belardi, Jorge A., Liu, Minglei, Brar, Sandeep, Rothman, Martin, and Windecker, Stephan

Abstract

Aim The optimal duration of dual antiplatelet therapy (DAPT) following the use of new generation drug-eluting stents is unknown. Methods and results The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme. Daily acetylsalicylate (ASA) and a thienopyridine for 6-12 months were prescribed. A DAPT interruption was defined as any interruption of ASA and/or a thienopyridine of >1 day; long interruptions were >14 days. Three groups were analysed: no interruption, interruption during the first month, and >1-12 months. There were 1069 (21.83%) patients with a DAPT interruption and 3827 patients with no interruption. Among the 166 patients in the 1-month interruption group, 6 definite/probable ST events occurred (3.61%; all long DAPT interruptions), and among the 903 patients in the >1-12 months (60% occurred between 6 and 12 months) interruption group, 1 ST event occurred (0.11%; 2-day DAPT interruption). Among patients with no DAPT interruption, 32 ST events occurred (0.84%). Rates of CD/TVMI were 6.84% in the 1-month long interruption group, 1.41% in the >1-12 months long interruption group, and 4.08% in patients on continuous DAPT. Conclusion In a pooled population of patients receiving an R-ZES, DAPT interruptions within 1 month are associated with a high risk of adverse outcomes. Dual antiplatelet therapy interruptions between 1 and 12 months were associated with low rates of ST and adverse cardiac outcomes. Randomized clinical trials are needed to determine whether early temporary or permanent interruption of DAPT is truly safe. Clinical Trials.gov identifiers NCT00617084; NCT00726453; NCT00752128; NCT00927940

Catalog

Books, media, physical & digital resources
See catalog results